Pancreatic involvement in patients with inborn errors of metabolism

Woo Jin Hwang1, Han Hyuk Lim1, Yoo-Mi Kim1, Mea Young Chang1, Hong Ryang Kil1, Jae Young Kim2, Wung Joo Song3, Harvey L. Levy4 and Sook-Za Kim1,3*

Abstract
Background: Repeated inflammation of the pancreas can cause pancreatitis or diabetes. It is well recognized that the organic acidemias may be complicated by pancreatitis but less recognized are other metabolic disorders in which pancreatitis can occur. This study shows that long-term follow-up of patients with various metabolic disorders in Korea revealed several with episodes of isolated pancreatitis or diabetes concomitantly with pancreatitis.

Results and discussion: In this study, two patients with methylmalonic aciduria (MMA), two with propionic acidemia (PPA), one with fatty acid oxidation disorder (FAOD), and one with hyperornithinemia, gyrate atrophy, and juvenile onset diabetes mellitus (DM) were clinically followed for up to 10 – 21 years. Two Korean siblings with MMA showed recurrent pancreatitis from the age of 15 and 19, respectively. The frequency of admission due to pancreatitis was up to 11 times. One patient with MMA developed diabetes mellitus at the age of 20. The other patient with MMA developed recurrent pancreatitis at 4 years and diabetes at 8 years of age. One of the patients with PPA presented with diabetic ketoacidosis. The other PPA patient died of cardiac arrest at age 10. The patient with FAOD presented with pancreatitis at 10 years and died at the age of 15 years due to cardiac arrest. A 35-year-old woman with hyperornithinemia/gyrate atrophy was diagnosed with juvenile onset diabetes at the age of 7 years. No pancreatitis occurred during the follow-up period.

Conclusions: We conclude that various metabolic disorders can trigger acute or chronic pancreatitis. Proper and prompt multidisciplinary management of metabolic derangement is crucial for preventing pancreatic damage. Further clinical and investigational studies are required to elucidate the pathogenesis of pancreatitis and diabetes mellitus in patients with inborn errors in metabolism.

Keywords: Pancreatitis, Diabetes mellitus, Inborn errors of metabolism, Methylmalonic aciduria, Propionic acidemia, Newborn screening, Hyperornithinemia, Fatty acid oxidation disorder

Introduction
Pancreatitis is the inflammation of the pancreas. Recurrent inflammation can damage the pancreas and progress to chronic pancreatitis. Fibrosis may form in the pancreas, resulting in loss of pancreatic function. A poorly functioning pancreas can cause digestive problems, abdominal pain, and diabetes mellitus (DM). The most common causes of acute pancreatitis (AP) in adults are alcohol consumption and presence of gallstones; however, in children, it is associated with a wide variety of potential etiologies, including idiopathic, trauma, drugs (asparaginase, mesalazine, opiates, etc.), infections (mumps, Epstein-Barr virus, Cytomegalovirus), systemic diseases (systemic lupus erythematosus, Henoch-Schönlein purpura, cystic fibrosis), and hereditary (Kazal type 1 gene (SPINK1) increase the susceptibility of chronic pancreatitis, PRSS1 is mutations of cationic trypsinogen
gene) and congenital anatomic anomalies [1]. Organic acidemia was first reported in 1994 as yet another cause of pancreatitis and accounts for 7% of the total pediatric cases of AP [2–7]. Although pancreatitis has been described in association with other disorders, even including phenylketonuria (PKU), [8] and in a Korean patient [9] pancreatitis is less well known in other categories of metabolic disorders [10, 11] and in Korean patients.

In cases of metabolic pancreatitis, management of the underlying causes is more important than the standard routine management of pancreatitis. The lack of proper metabolic management can lead to recurrent bouts of AP [11].

Herein, we report a Korean experience with AP and complications in different metabolic disorders. The complications include recurrent pancreatitis and DM. Our report emphasizes the occurrence of pancreatitis in different metabolic disorders among Korean patients and the need for careful metabolic therapy to lower the risk of pancreatitis and also to treat AP when it occurs.

Patients and methods
Six patients (5 men and 1 woman) with inborn errors of metabolism who had experienced complications involving the pancreas were included in this study.

Two patients with methylmalonic aciduria (MMA), two patients with propionic acidemia (PPA), one patient with fatty acid oxidation disorder (FAOD), and one patient with hyperornithinemia, gyrate atrophy, and juvenileson DM were clinically followed up for 10–20 years at the Chungnam National University Hospital and/or Kim SZ Children’s Hospital.

The six patients were evaluated clinically. Laboratory evaluation included serum amylase and lipase tests, renal clearance assay based on urine creatinine level, and pancreatic auto antibody tests.

Serum amylase and lipase levels were measured using colorimetric assays, where a spectrophotometer was used to measure the absorbance of the samples at 420 nm. A tandem mass spectrometer (MS/MS) (Micromass Quattro spectrometer) was used for metabolic screening. The plasma and urine amino acid levels were measured using an ion exchange chromatography amino acid analyzer (Hitachi high-speed amino acid analyzer L-8900). Renal clearances were calculated based on the urine creatinine level. Organic acid content was measured using gas chromatography-mass spectrometry (Agilent). Pancreas autoantibody tests were performed at other laboratories.

Metabolic tests for inborn metabolic disorders were performed using tandem mass spectrometry (metabolic screening), plasma and urine amino acid analysis, and organic acid analysis.

We applied the diagnostic criteria of AP (at least two of the following three features):

1. Acute onset of upper abdominal pain, nausea, vomiting
2. Serum amylase and/or lipase ≥ 3 times the upper limit of the normal local range
3. Imaging findings characteristic of AP

The diagnostic criteria of DM symptoms included polyuria/polydipsia/weight loss, fasting glucose > 126 mg/dL or random glucose > 200 mg/dL, and hemoglobin A1c ≥ 6.5%.

Autoimmune diabetes was determined by the presence of autoimmunity against one or more of the following antibodies: islet cell autoantibodies (ICA), autoantibodies to glutamic acid decarboxylase (GAD), and insulin autoantibodies (IAA).

Case reports
The pancreatic involvement of patients is summarized in Table 1. Their clinical manifestation and biochemical findings are shown in Table 2.

MMA cases
Case 1 was a 20-year-old man with MMA. He was born via cesarean section because of placenta previa at gestational age of 37 weeks with birth weight of 2.7 kg. Due to positive family history (his brother had MMA), he underwent metabolic investigation. His metabolic evaluation revealed blood ammonia level of 400–500 mg/dL and elevated C3 carnitine level (48.8; reference range, < 4.1). The methylmalonic acid level in urine was 1617 µg/mg Cr, and elevation in plasma glycine (415 µmol/L) and alanine (978 µmol/L) levels were noted. Cobalamin (Cbl) incorporation study of 14C-propionate showed lack of response to Cbl (i.e. mut³) and slightly low response to adocobalamin (AdoCbl). Molecular investigations revealed a compound heterozygous c.1105C>T(p.R369C), p.G94Q mutation. He was fed with special formula (Propiomex), regular infant formula, low-protein food, and L-carnitine supplement (100 mg/kg/d). His developmental evaluation at 20 months of age showed a mild delay. Prior to 5 years of age, blood urea nitrogen (BUN) and creatinine were in the normal range (BUN 6.6–12.3 mg/dL /creatinine 0.7–0.8 mg/dL). However, after 5.5 years of age, his renal function slowly deteriorated, showing a BUN level of 16.2–29.2 and creatinine level of 0.81–1.02. He was hospitalized multiple times due to metabolic decompensations (acidosis, dehydration, and hyperammonemia) after trivial infections or skipping of the special formula. At 6 years of age, his eye sight deteriorated progressively and he became legally blind due to optic atrophy by 10 years.
of age. He received growth hormone treatment for metabolic induction to anabolism and improvement of his short stature. At 15 years of age, he experienced vomiting and abdominal pain due to pancreatitis. His metabolic status became unstable; he was hospitalized more than 7 times with pancreatitis (Table 1). At this time, he began to experience hand tremors due to his metabolic condition. After recurrent pancreatitis at 19 years of age, he showed glucose intolerance. By the age of 20 years, he developed DM, requiring insulin injection. His most recent metabolic crisis was accompanied by severe metabolic acidosis (pH 6.8), liver dysfunction (aspartate aminotransferase (AST) 245 IU/L, alanine aminotransferase (ALT) 316 IU/L), hyperventilation, hemorrhagic gastritis, and left pleural effusion. His pancreatic amylase and lipase levels were >4000 U/L. He was put on continuous renal replacement therapy for 3 days. During the metabolic crisis, he experienced seizures and hand tremors, although the results of brain magnetic resonance imaging (MRI) and electroencephalogram (EEG) were normal. The abdominal computed tomography (CT) showed necrotizing pancreatitis and follow-up ultrasound after 1 month of pancreatitis showed a pancreatic pseudocyst. His renal function progressively deteriorated, showing a BUN level of 40.1–60 mg/dL, Cr level of 2.04–2.81 mg/dL, and estimated glomerular filtration rate (eGFR) level of 43.7 mL/min/1.73 m². His metabolic parameters were as follows: pH, 7.30–7.31; HCO₃ level, 11.2–20.6; methylmalonic acid level, 1768–3861 µg/mg Cr; glycine level, 625–1187 µmol/L (normal range: 158–302 µmol/L); alanine level, 508–825 µmol/L (normal range: 185–537 µmol/L). His ferritin levels were 280–581.53 ng/mL (normal range: 50–200 ng/mL). His current weight is 46.1 kg and height is 164 cm. He has recovered completely from pancreatitis, and his glucose levels are being controlled using insulin (Table 2).

Case 2 is the 21-year-old elder brother of Case 1. He was born via cesarean section because of placenta previa at a gestational age of 37 weeks, with a birth weight of 2.47 kg, to a 21-year-old mother who had a

---

**Table 1 Pancreatic manifestation and precipitating factors of hereditary metabolic disorders**

| Age (years) | Number of hospitalizations | Precipitating factors | Pancreatic disorders |
|-------------|----------------------------|-----------------------|---------------------|
| MMA (Case 1) | 15 | 1 | Dehydration, fever, poor oral intake, liver dysfunction | Pancreatitis, Diabetes, Mellitus |
| MMA (Case 1) | 16 | 3 | | |
| MMA (Case 1) | 19 | 2 | | |
| MMA (Case 1) | 20 | 1 | | |
| MMA (Case 2) | 21 | 1 | Respiratory infection, weight loss, bronchial asthma, vomiting, dehydration | Pancreatitis, Diabetes |
| PPA (Case 3) | 14 | 1 | Diabetes mellitus for 14 years | Diabetes |
| PPA (Case 4) | 4 | 1 | Surgery for intestinal obstruction, swine flu, fever, dehydration, ferritinemia | Pancreatitis, Diabetes |
| FAO (Case 5) | 10 | 1 | Fasting, dehydration | Pancreatitis |
| Ornithine (Case 6) | 33 | None | No diet control for ornithine | Diabetes |

**Table 2 Clinical history of patients with hereditary metabolic disorders**

| Underlying disease | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 |
|--------------------|--------|--------|--------|--------|--------|--------|
| MMA                | 20 y/M | MMA    | PPA    | PPA    | FAO    | Hyperornithinemia |
| MMA                | 15 y/M | PPA    | PPA    | PPA    | FAO    | Hyperornithinemia |
| Age (years)        |        | 14 y/M | 10 y/M | 15 y/M | 15 y/M | 35 y/M |
| Birth history      |        | GA 37 wks, 2.7 kg, C/sec | GA 36 wks, 3.2 kg, C/sec | Full term, 3.7 kg, NSVD | Full term, NSVD | Full term, 3.73 kg, NSVD |
| Age of diagnosis   | Perinatal period | Perinatal period | Perinatal period | Perinatal period | 40 m | 7 y |
| NH₃ (µg/dL)        | > 1000 | 400    | 1200   | 300    | Normal |
| Management         | Special formula (Propimex) | Low-protein diet | Special formula (MPA) | Insulin | Freq. feeding | Raw corn starch |
|                    | Low-protein diet | L-carnitine supplement | | | | Low-protein diet |
history of spontaneous miscarriage. Within a few days after birth, he started vomiting, and showed poor feeding, seizures, and lethargy. He was transferred to a university hospital, where he was found to have blood ammonia level of over 1000 mg/dL and acute metabolic acidosis. At 2 weeks of age, he was diagnosed with MMA by urine organic acid analysis. After peritoneal dialysis, he was in the neonatal intensive care unit (NICU) for 2 weeks for metabolic control. Until 4.5 years of age, multiple hospitalizations for metabolic crises followed, as a special metabolic formula was not available in South Korea at that time. After obtaining a special formula (Propiomex) from overseas, regular baby formula and low-protein food became a part of the ongoing metabolic management and his metabolic status was stabilized. Cbl incorporation study of 14C-propionate showed no response to cobalamin (i.e. mut0) and slightly low response to AdoCbl. Similar to Case 1, the molecular study revealed the presence of the 1105C>T(p.R369C), p.G94Q mutation. He began receiving growth hormone treatment at the age of 11 years for metabolic induction to anabolism and improvement of his short stature. His biochemical parameters were as follows: pH, 7.29–7.4; pCO2, 38.1; pO2, 62.8; HCO3 level, 9.6–23.6; base excess level, −1.1; SO2 level, 82–93.5%. His blood ammonia level was 84–126 µg/dL, lactic acid level was 2.0–1137 µg/mg Cr (normal range: 6–61 µg/mg Cr), propionyl-CoA carboxylase (PCC) activity [124 pmol/min/mg protein (reference: > 31 pmol/min/mg)], normal methylmalonyl-CoA carboxylase (MCC) activity [55 pmol/min/mg protein (reference: > 31 pmol/min/mg)], and normal pyruvate carboxylase (PC) activity [124 pmol/min/mg protein (reference: > 71)]. Propionyl carboxylase assay using biotin-supplemented culture medium showed that he was non-responsive to biotin. He was fed breast milk exclusively and an unrestricted normal regular diet. However, at 23 months of age, he was hospitalized for metabolic decompensation and hyperammonemia following rotavirus gastroenteritis. Special formula for PPA was introduced after that. The patient was not compliant with the PPA formula because of its taste. He was admitted to the hospital 12 times due to metabolic decompensation (i.e. metabolic acidosis and hyperammonemia) at 23 months of age. The unusual clinical presentation was recurrent headache, which was relieved by intravenous glucose/electrolyte infusion. At 13 years, he was diagnosed with Osgood-Schlatter disease. At 14 years of age, ophthalmologic evaluation revealed Avellino corneal dystrophy. He experienced diabetic ketoacidosis, which was associated with weight loss. His blood glucose level was 2018 mg/dL and C-peptide level was 0.87 ng/mL (reference: 0.81–3.86 ng/mL). His autoantibody profile was as follows: islet cell antibody (Ab)-negative, insulin Ab-negative, and anti-GAD Ab level < 0.11 (reference: ≤ 1.00 U/mL). Insulin was administered to the patient, after which he became compliant with the PPA special formula for diet control (Table 2). His long-term metabolic profile revealed glycine level of 261–314 µmol/L (normal range: 158–302 mmol/L), alanine level of 703 mmol/L (normal range: 185–537 mmol/L), glutamine level of 429 µmol/L (normal range: 360–740 µmol/L), methylmalonic acid level of 1182–1444 µg/mg Cr, lactic acid level of 1137 µg/mg Cr (normal range: 6–61 µg/mg Cr), and elevation of the 3-hydroxypropion process and methylcitric acid levels. His current weight and height are 61 kg and 165 cm, respectively. He showed developmental delay (walking and speech at the ages of 20 months and 43 months, respectively). He is now independent and has a full-time job at a coffee shop. Recently, he had been hospitalized for headache and decreasing visual acuity. He was diagnosed with essential hypertension and treated with calcium channel blocker.

**PPA cases**

Case 3 was a 14-year-old boy. He was born via normal spontaneous vaginal delivery (NSVD) without complication at the gestational age of 36 weeks, with birth weight of 3.2 kg. C3 carnitine level elevation (37, reference: < 4.1) was detected in the expanded newborn screening program. His urine organic acid analysis confirmed PPA. His blood gas and blood ammonia levels were normal. The fibroblast carboxylase assay revealed reduced propionyl-CoA carboxylase (PCC) activity [9 pmol/min/mg protein (reference: > 91 pmol/min/mg)], normal methylcrotonyl-CoA carboxylase (MCC) activity [55 pmol/min/mg protein (reference: > 31 pmol/min/mg)], and normal pyruvate carboxylase (PC) activity [124 pmol/min/mg protein (reference: > 71)]. Propionyl carboxylase assay using biotin-supplemented culture medium showed that he was non-responsive to biotin. He was fed breast milk exclusively and an unrestricted normal regular diet. However, at 23 months of age, he was hospitalized for metabolic decompensation and hyperammonemia following rotavirus gastroenteritis. Special formula for PPA was introduced after that. The patient was not compliant with the PPA formula because of its taste. He was admitted to the hospital 12 times due to metabolic decompensation (i.e. metabolic acidosis and hyperammonemia) at 23 months of age. The unusual clinical presentation was recurrent headache, which was relieved by intravenous glucose/electrolyte infusion. At 13 years, he was diagnosed with Osgood-Schlatter disease. At 14 years of age, ophthalmologic evaluation revealed Avellino corneal dystrophy. He experienced diabetic ketoacidosis, which was associated with weight loss. His blood glucose level was 2018 mg/dL and C-peptide level was 0.87 ng/mL (reference: 0.81–3.86 ng/mL). His autoantibody profile was as follows: islet cell antibody (Ab)-negative, insulin Ab-negative, and anti-GAD Ab level < 0.11 (reference: ≤ 1.00 U/mL). Insulin was administered to the patient, after which he became compliant with the PPA special formula for diet control (Table 2). His long-term metabolic profile revealed glycine level of 261–314 µmol/L (normal range: 158–302 µmol/L), significantly elevated glutamine level of 1169–1545 µmol/L (normal range: 360–740 µmol/L), and small amounts of 3-hydroxypropionic acid, propionyl glycine, and methyl citrate. His amylase level had always been normal at 81–90 U/L (reference: 28–100 U/L) during our long-term follow-up.

Case 4 was a patient with PPA. He was born via NSVD at full-term without complications, and his birth weight was 3.7 kg. C3 carnitine level elevation (63, reference:
and 3-methylglutaconic aciduria during a metabolic cri-organic acid analysis revealed hypoketotic hypoglycemia. He was administered deferoxamine to lower the fer-

Case of fatty acid oxidation disorder
Case 5 was a 15-year-old boy with cerebral palsy. He was born via NSVD to a 21-year-old mother (G2P1 SAB) with a birth weight of 3.73 kg. He had tunnel vision, myopia, and night blindness at the age of 5 years. At the age of 7, she was diagnosed with juvenile-onset diabetes. She had menarche when she was 16 years old. She was evaluated metabolically at the age of 34 and high ornithine levels were detected in her blood and urine. Hyperornithine-

Gyrate atrophy with hyperornithinemia
Case 6 was a 35-year-old woman who was confirmed to be blind and diabetic. She was born at full term via NSVD to a 21-year-old mother (G2P1 SAB) with a birth weight of 3.73 kg. She had tunnel vision, myopia, and night blindness at the age of 5 years. At the age of 7, she was diagnosed with juvenile-onset diabetes. She had menarche when she was 16 years old. She was evaluated metabolically at the age of 34 and high ornithine levels were detected in her blood and urine. Hyperornithine-

Hwang et al. Orphanet J Rare Dis (2021) 16:37
normal without murmurs. Regarding the extremities, she had short limbs, thick and short fingers, missing knuckles of the 4th fingers, abnormally long 2nd and 4th toes, pitting edema, and mildly short Achilles tendons. She had subcutaneous nodules on both legs, lipodystrophy on the injection sites of the abdomen, and brisk DTR. In addition, her visual field was extremely constricted and her fundi showed abnormal pigmentation, sparing a small proportion of the retina. Ophthalmologic examination revealed isocoric pupils, clear corneas, pale fundi, and thin retinal vessels; she also had limitations of extraocular muscle movements in all directions, with nystagmus. Plasma amino acid analysis showed ornithine levels of 756–900 µmol/L (reference: 106 µmol/L). After the diagnosis of gyrate atrophy of the choroid and retina associated with hyperornithinemia, she was fed a low-protein diet (Table 2). During the follow-up, she did not have pancreatitis (Table 3).

**Discussion**

In this report we described pancreatitis in 6 Korean patients with metabolic disorders, 4 with an organic acid disorder, one with a fatty acid oxidation disorder, and one with an aminoacidopath. Thus, our experience over a period of 10–20 years emphasizes the ubiquity of pancreatitis among the metabolic disorders as well as the need for careful and complicated metabolic therapy when pancreatitis occurs.

A large number of patients with pancreatitis develop glucose intolerance or DM; islet β-cell injury in pancreatitis may explain the occurrence of glucose intolerance or DM. However, α-cell function can be equally important, as selective α-cell destruction prevents the hyperglycemic response associated with pancreatitis [12]. It has been accepted that injury to islet cells in chronic pancreatitis results in insulin deficiency; however, normal or elevated fasting plasma insulin levels in patients with chronic pancreatitis do not support the expected findings [13, 14].

In this report, Case 1 (MMA) had both diabetes and pancreatitis, but Case 3 (PPA) and Case 6 (hyperornithinemia with gyrate atrophy) had diabetes with normal pancreatic enzyme levels. All three patients showed negative results in the pancreatic autoantibody panel. These findings may suggest the presence of chronic adverse alterations in pancreatic cells due to metabolic insults and toxic compounds associated with metabolic disorders.

Not only is acute and chronic accumulation of organic acids toxic to pancreatic cells, but lactic acid, uric acid, and acidosis may also affect the injury to pancreatic tissue. Reports show that glycogen storage disease type I (von Gierke disease) is associated pancreatitis [15–18]. The mechanism underlying the development of pancreatitis has been elucidated, although the most common biochemical changes in the disease include hypoglycemia, lactic acidosis, and high levels of uric acid and triglycerides—any of which may contribute to the onset of pancreatitis. Previous studies have reported the incidence of pancreatitis in organic acidurias; the first ever report discussed pancreatitis in 9 out of 108 patients with branched-chain organic aciduria (BCOA) [2, 7], while pancreatitis was observed in 10 patients with isovaleric academia [19, 20], 2 with propionic academia [4, 6], 1 with MMA [6], 2 with maple syrup urine disease (MSUD) [21], 1 with glutaric academia [5], and 2 with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency [22, 23]. Case 5, who had a fatty acid oxidation metabolic disorder, showed elevated transaminase levels and hepatomegaly after prolonged fasting or inadequate diet, which led to pancreatitis. Lack of energy supply could be

**Table 3** Laboratory data of hereditary metabolic disorders

| Underlying disease | MMA (Case 1) | MMA (Case 2) | PPA (Case 3) | PPA (Case 4) | FAOD (Case 5) | Hyperornithinemia (Case 6) |
|-------------------|-------------|-------------|-------------|-------------|--------------|--------------------------|
| Pancreatitis      | +           | +           | −           | +           | +            | −                        |
| Amylase during metabolic crisis (IU/L) | > 4000 | 176–215 | 81–90 | 317–558 | 122–808 | − |
| Lipase (range)    | > 4000      | 100         | −           | 347–1585   | 493–13,978  | −                        |
| Onset of AP       | 15 y        | 19 y        | −           | 4 y         | 10 y         | −                        |
| No. of episodes   | 7           | 1           | 1           | 5           | 1            | None                     |
| Diabetes mellitus (DM) | DM | −         | +           | +           | −            | +                        |
| DM_onset         | 20 y        | 14 y        | 8 y         | −           | 7 y          | −                        |
| DM_management    | Insulin     | Insulin     | Insulin     | Insulin     | Insulin      | −                        |

*MMA* methylmalonic academia, *PPA* propionic academia, *FAOD* fatty acid oxidation disorder, *HO* hyperornithinemia
a precipitating factor of pancreatitis. Treatment involving glucose electrolyte solution alleviated the hepatomegaly and decreased the transaminase level to normal. The liver function profile showed elevation of AST and ALT levels, with normal levels of bilirubin. Case 6 (hyperornithinemia with gyrate atrophy) has DM but, interestingly, pancreatitis was never noted in her medical record or during numerous clinical follow-ups emphasizing the need for diligence in any patient with a metabolic disorder who develops DM. Lipid metabolic disorders such as hyperlipidemia appear to be one of the most common inherited causes of recurrent pancreatitis. This includes hereditary lipoprotein lipase deficiency [24–27], familial hypertriglyceridemia, chylomicronemia (type I & V), hyperlipoproteinemias [28], and apolipoprotein C-II deficiency. In particular, pancreatitis represents frequent and sometimes severe complications of apolipoprotein C-II deficiency; up to 60% patients with apolipoprotein C-II deficiency are affected by episodes of pancreatitis [29–31]. Hyperlipidemia interferes with amylose measurements, leading to false-negative results [20, 21, 26, 27, 32, 33]. This may explain the normal or mildly elevated amylose levels in patients with severe necrotizing pancreatitis.

The observations regarding other amino acid metabolic disorders varied. Postmortem histology of patients with homocystinuria (cystathionine β-synthase deficiency) and pancreatitis has revealed marked fibrous thickening of the intima, and frayed and split muscle and elastic fibers of the media without lipid deposition in most large- or medium-sized arteries [28, 34, 35]; thus, blood circulation to the pancreas may have been compromised. Cystinuria is associated with familial pancreatitis [36]. Duct calculi in patients with cystinuria, chronic renal insufficiency or renal failure may adversely affect the pancreas [37, 38]. Lysinuric protein intolerance leads to inflammatory changes, necrosis, intraductal protein plugs, atrophy, and fibrosis in the pancreas [39, 40]. Furthermore, pancreatitis has been reported in patients with pyruvate kinase deficiency [41] and acute intermittent porphyria [42–46].

**Conclusion**

Pancreatitis is not a common complication of the inborn errors of metabolism, and is often overlooked during the treatment and management of patients with metabolic disorder. Yet, acute pancreatitis can accompany abdominal pain, exacerbate vomiting episodes, and cause subsequent rapid metabolic deterioration. Acute or chronic pancreatitis may complicate the condition of patients with inborn errors of metabolism. Pancreatitis must be considered in patients with these disorders who have acute clinical deterioration and vomiting, abdominal pain, encephalopathy or shock, or milder symptoms. Inborn error of metabolism should be considered in children with pancreatitis of unknown origin. While the pathophysiology may vary in different cases, pancreatitis should be monitored not only in cases of metabolic disorders involving hyperlipidemia, but also in cases of amino acid, organic acid, and fatty acid oxidation disorders, as well as in cases of heme and pyruvate metabolic disorders.

Early diagnosis and management of pancreatitis may prevent long-term complications such as type 2 DM. Further studies are required to elucidate the pathogenesis of pancreatitis, as well as of DM associated with hereditary metabolic disorders.

**Abbreviations**

MMA: Methylmalonic aciduria; PPA: Propionic acidemia; FAOD: Fatty acid oxidation disorder; DM: Diabetes mellitus; AP: Acute pancreatitis; MS/MS: Tandem mass spectrometer; ICA: Islet cell autoantibodies; GAD: To glutamic acid decarboxylase; IAA: Insulin autoantibodies; AdoCbl: Adocobalamin; Cbl: Cobalamin; BUN: Blood urea nitrogen; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; MRI: Magnetic resonance imaging; EEG: Electroencephalogram; CT: Computed tomography; NICU: Neonatal intensive care unit; NSVD: Normal spontaneous vaginal delivery; PCC: Propionyl-CoA carboxylase; MCC: Methylcrotonyl-CoA carboxylase; PC: Pyruvate carboxylase; NSVD: Normal spontaneous vaginal delivery; SIADH: Syndrome of inappropriate antidiuretic hormone; ICU: Intensive care unit; LDH: Lactic dehydrogenase; CPK: Creatine phosphokinase; GAD: Generalized Anxiety Disorder; HC: Head circumference; DTR: Deep tendon reflex; BCOA: Branched-chain organic aciduria.

**Acknowledgements**

This work uses data provided by patients and collected by the Chonnam National University Hospital Medical Records Room as part of their care. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people’s patient records, to understand more about disease, develop new treatments, monitor safety, and plan medical services. Patient data should be kept safe and secure, to protect everyone’s privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data is used. We gratefully acknowledge the cooperation and the patience of the patients, who made this work possible.

**Authors’ contributions**

Woo Jin Hwang collected information from medical records and was involved in the writing of the manuscript. Han Hyuk Lim supervised by IRB(Institutional Review Board) guideline. Yoo-Mi Kim corrected the manuscript and provided the molecular work for this study. Mea Young Chang provided patient’s care, follow-up and corrected the manuscript. Hong Ryang Ki provided patient’s care, follow-up information and laboratory interpretation. Jae Young Kim provided patient’s care, follow-up and treated pancreatitis. Wung Joo Song wrote paper, made table and corrected English. Harvey L. Levy provided guidance of the paper writing and review of manuscript. Sook-Za Kim wrote paper and published the paper. All authors read and approved the final manuscript.

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article and its supplementary information. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study protocol and study methodology was approved by ethic committees in Korea (Chungnam National University Hospital Institutional Review Board, IRB File No. CNUH 2019-03-085). All participants gave a written informed consent; in case of the inability to give written consent, a legal representative had to provide consent.

Consent for publication
See the attached files.

Competing interests
No potential conflict of interest relevant to this article was reported.

Author details
1 Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Korea. 2 Department of Pediatrics, Gyeongsang National University Hospital, Changwon-si, Gyeongsangnam-do, Korea. 3 Korea Genetics Research Center, Cheongju, Korea. 4 Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, USA.

Received: 5 October 2020 Accepted: 6 January 2021
Published online: 20 January 2021

References
1. Türkvatan A, Erden A, Türkoglu MA, Yener Ö. Congenital variants and anomalies of the pancreas and pancreatic duct: imaging by magnetic resonance cholangiopancreatography and multidetector computed tomography. Korean J Radiol. 2013;14(6):903–13.
2. Kahler SG, Sherwood WG, Woolf D, Lawless ST, Zaritsky A, Bonham J, Taylor CJ, Clarke JT, Durie P, Leonard JV. Pancreatitis in patients with organic acidemias. J Pediatr. 1994;124:239–43.
3. Majbar AA, Cusick E, Johnson P, Lynn RM, Hunt LP, Shield JP. Incidence and clinical associations of childhood acute pancreatitis. Pediatrics. 2016;138(2):e20161198.
4. Burlina AB, Dionisi-Vici C, Piovano S, Saponara I, Bartuli A, Sabetta G, Zacchello F. Acute pancreatitis in propionic acidemia. J Inherit Metab. 1995;18:169–72.
5. Lermie EG, Moroz S, Pollock B, Postuma R, Greenberg CR. Acute pancreatitis in a patient with glutaric aciduria type II. J Pediatr. 1996;128:589–90.
6. Bultron G, Seashore MR, Pashankar DS, Husain SZ. Recurrent acute pancreatitis associated with propionic acidemia. J Pediatr Gastroenterol Nutr. 2008;47:370–1.
7. Marquard J, El Scheich T, Klee D, Schmitt M, Meissner T, Mayatepek E, Oh J-H. Chronic pancreatitis in branched-chain organic acidurias—a case of methylmalonic aciduria and an overview of the literature. Eur J Pediatr. 2011;170:241–5.
8. Bertrand V, Smolikova E, Masson E, Bruel H. Severe acute pancreatitis in a child with phenylketonuria. Arch Pediatr. 2019;26:115–7.
9. Choe JY, Jang KM, Min SY, Hwang SK, Kang B, Choe BH. Propionic acidemia with novel mutation presenting as recurrent pancreatitis in a child. Korean J Med Sci. 2019;34:e303.
10. Simon P, Weiss FU, Zimmer KE, Koch GH, Lerch MM. Acute and chronic pancreatitis in patients with inborn errors of metabolism. Pancreatology. 2003;1:448–56.
11. Kota SK, Krishna SVS, Lakhatkia S, Modi KD. Metabolic pancreatitis: etiopathogenesis and management. Indian J Endocrinol Metab. 2013;17:799–805.
12. Bridgewater AB, Ogawa T, Chiles T, Necheles H. Transient increase in blood sugar following experimental pancreatitis. Amer J Physiol. 1961;200:851–4.
13. Peters N, Dick AP, Hales CN, Orell D, Sanner M. Exocrine and endocrine pancreatic function in diabetes mellitus and chronic pancreatitis. Gut. 1966;277–281.
14. Keller P, Bank S, Jackson WP, Marks IN, O'Reilly KG. Plasma insulin levels in "pancreatic diabetes." Lancet. 1965;2:1211–3.
15. Michels VJ, Beaudet AL. Hemorrhagic pancreatitis in a patient with glycogen storage disease type I. Clin Genet. 1980;17:220–2.
16. Kikuchi M, Hasegawa K, Handa I, Watabe M, Narisawa K, Tada K. Chronic pancreatitis in a child with glycogen storage disease type I. Eur J Pediatr. 1991;150:852–3.
17. Herman TE. Type IA glycogenosis with acute pancreatitis (in French). J Radiol. 1995;76:51–3.
18. Lesser PR, Warshaw AL. Diagnosis of pancreatitis masked by hyperlipemia. Ann Intern Med. 1975;82:795–8.
19. Tokatli A, Coşkun T, Ozalp I. Isovaleric acidemia: clinical presentation of 6 cases. Turk J Pediatr. 1998;40:111–9.
20. Mantadakis E, Chrysafis I, Tsouvala E, Evangelou A, Chatzimichail A. Acute pancreatitis with rapid clinical improvement in a child with isovaleric acidemia: case Rep Pediatr 2013;721871.
21. Friedrich CA, Marble M, Maher J, Valle D. Successful control of branched-chain amino acids (BCAA) in maple syrup urine disease using elemental amino acids in total parenteral nutrition during acute pancreatitis. Ann J Hum Genet. 1992;51:4350.
22. Gmaz-Nikulin E, Nikulin A, Flamanac P, Hegenwald G, Gaon D. Pancreatic lesions in shock and their significance. J Pathol. 1981;135:232–36.
23. Kliger V, Kluger L. Hereditary pancreatitis (in Hungarian). Orv Hetil 1989;130:1777–8.
24. Brunzell JD, Schrott HG. The interaction of familial and secondary causes of hypertriglyceridaemia: role in pancreatitis. Trans Assoc Am Phys. 1973;86:245–54.
25. Siafakas CG, Brown MR, Miller TL. Neonatal pancreatic associated with familial lipoprotein lipase deficiency. J Pediatr Gastroenterol Nutr. 1999;29:95–8.
26. Wilson DE, Hata A, Kwong LW, Lingam A, Shuha J, Ridinger DN, Yaeger C, Kaltenborn KC, Iverhus PH, Labolod JM. Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridaemia, pancreatitis, and non-insulin-dependent diabetes. J Clin Invest. 1993;92:203–11.
27. Cameron JL, Capuzzi DM, Zuidema GD, Morgulis S. Acute pancreatitis with hyperlipidaemia: the incidence of lipid abnormalities in acute pancreatitis. Ann Surg 1973;177:485–489.
28. Levy RI, Fredrickson DS. Familial hyperlipoproteinemia; in: Stanbury JB, Wyngaarden JB, Fredrickson DS (eds): The Metabolic Basis of Inherited Disease, ed 3. New York, McGraw-Hill, 1972. p. 545.
29. Greenberger NJ, Hatch FT, Drumsey GD, Isselbacher KJ. Pancreatitis and hyperlipidaemia: a study of serum lipid alterations in 25 patients with acute pancreatitis. Medicine (Baltimore). 1966;45:161–8.
30. Dominguez-Munoz JF, Malfertheiner P, Dutschnecht HJ, Blanco-Chavez U, Ulrich JA. Hypertriglyceridemia and pancreatitis: possible complications of patients with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency. J Inherit Metab Dis. 1991;150:852–3.
31. Iyer E, Arikinda A, Weiss D, Dubin Z, Yatziv S. Gastrointestinal involvement in homocystinuria. J Gastroenterol Hepatol. 1993;8:60–2.
32. Gross JB, Ulrich JA, Jones JD. Urinary excretion of amino acids in a kindred with hereditary pancreatitis and aminocaciduria. Gastroenterology. 1964;47:41–8.
33. Gerok WR, Winkelman EI, Brown HB, Lewis LA. Hypertriglyceridemia and pancreatitis. Ann Intern Med. 1973;79:186–7.
34. Compton D, Yancey J, Uhl W, Buchler M, Dutschnecht H. Hyperlipidaemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol 1991;10:261–267.
35. Breckenridge WC, Little JA, Steinig G, Chow A, Poapst M. Hypertriglyceridaemia associated with deficiency of apolipoprotein C-II. N Engl J Med. 1978;298:1265–73.
36. Farmer RG, Winkelman EI, Brown HB, Lewis LA. Hyperlipoproteinemia and pancreatitis. Am J Med. 1973;54:161–5.
37. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am. 1990;19:783–91.
38. Cox DW, Breckenridge WC, Little JA. Inheritance of apolipoprotein C-II deficiency with hypertriglyceridaemia and pancreatitis. N Engl J Med. 1978;299:1421–4.
39. Collins JE, Brenton DP. Pancreatitis and homocystinuria. J Inherit Metab Dis. 1991;14:312–3.
40. Makins RJ, Gertner DJ, Lee PJ. Acute pancreatitis in homocystinuria. J Inherit Metab Dis. 2000;23:190–1.
41. Ilan Y, Eid A, Rikvidik A, Weiss D, Dubin Z, Yatziv S. Gastrointestinal involvement in homocystinuria. J Gastroenterol Hepatol. 1993;8:60–2.
42. Gross JB, Ulrich JA, Jones JD. Urinary excretion of amino acids in a kindred with hereditary pancreatitis and aminocaciduria. Gastroenterology. 1964;47:41–8.
43. Lerch MM, Riehl J, Mann H, Nolte I, Sieberth HG, Matern S. Sonographic changes of the pancreas in chronic renal failure. Gastroent Radiol. 1989;14:311–4.
44. Lerch MM, Hoppe-Seley P, Gerek O. Origin and development of exocrine pancreas insufficiency in experimental renal failure. Gut. 1994;35:401–7.
45. Muroi J, Yorfufji T, Uematsu A, Nakahta T. Cerebral infarction and pancreatitis: possible complications of patients with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency. J Inherit Metab Dis. 2000;23:636–7.
42. Wilson WG, Cass MB, Sovik O, Gibson MK, Sweetman L. A child with acute pancreatitis and recurrent hypoglycemia due to 3-hydroxy-3-methylglutaryl-CoA lyase deficiency. Eur J Pediatr. 1984;142:289–91.
43. Mahour GH, Lynn HB, Hill RW. Acute pancreatitis with biliary disease in erythrocyte pyruvate-kinase deficiency. Case report and comments on management. Clin Pediatr (Phila) 1969;8:608–10.
44. Lam J, Loyola ME, Contreras L. High lipase level in a patient with porphyria crisis: cause of confusion with acute pancreatitis (in Spanish). Rev Med Chil. 1996;124:1273–4.
45. Shiraki K, Takase K, Tameda Y, Kosaka Y. Acute pancreatitis associated with acute intermittent porphyria (in Japanese). Nihon Rinsho. 1995;53:1479–83.
46. Shiraki K, Matsumoto H, Masuda T, Watanabe K, Takase K, Nakano T, Tameda Y, Kosaka Y. A case of acute intermittent porphyria with acute pancreatitis. Gastroenterol Jpn. 1991;26:90–4.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.